JP2021530989A5 - - Google Patents

Info

Publication number
JP2021530989A5
JP2021530989A5 JP2021500868A JP2021500868A JP2021530989A5 JP 2021530989 A5 JP2021530989 A5 JP 2021530989A5 JP 2021500868 A JP2021500868 A JP 2021500868A JP 2021500868 A JP2021500868 A JP 2021500868A JP 2021530989 A5 JP2021530989 A5 JP 2021530989A5
Authority
JP
Japan
Prior art keywords
domain
igg1
domain monomer
monomer
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021500868A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530989A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/041306 external-priority patent/WO2020014419A2/en
Publication of JP2021530989A publication Critical patent/JP2021530989A/ja
Publication of JP2021530989A5 publication Critical patent/JP2021530989A5/ja
Withdrawn legal-status Critical Current

Links

JP2021500868A 2018-07-11 2019-07-11 ＰＤ−Ｌ１を標的とした改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法 Withdrawn JP2021530989A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696711P 2018-07-11 2018-07-11
US62/696,711 2018-07-11
PCT/US2019/041306 WO2020014419A2 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1

Publications (2)

Publication Number Publication Date
JP2021530989A JP2021530989A (ja) 2021-11-18
JP2021530989A5 true JP2021530989A5 (https=) 2022-07-20

Family

ID=69141681

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500868A Withdrawn JP2021530989A (ja) 2018-07-11 2019-07-11 ＰＤ−Ｌ１を標的とした改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法

Country Status (11)

Country Link
US (1) US20210147549A1 (https=)
EP (1) EP3820998A4 (https=)
JP (1) JP2021530989A (https=)
KR (1) KR20210044782A (https=)
CN (1) CN112996910A (https=)
AU (1) AU2019299935A1 (https=)
BR (1) BR112021000383A2 (https=)
CA (1) CA3106108A1 (https=)
IL (1) IL280038A (https=)
MX (1) MX2021000281A (https=)
WO (1) WO2020014419A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024219897A1 (ko) * 2023-04-21 2024-10-24 상트네어바이오사이언스 주식회사 두 개의 fab 도메인 및 두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
EP4700047A1 (en) * 2023-04-21 2026-02-25 Centenaire Biosciences, Inc. Antigen-binding protein containing two fc domains and use thereof
CN117736329B (zh) * 2023-12-25 2024-11-12 华润生物医药有限公司 抗pd-1抗体及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101764096B1 (ko) * 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
SG11201405226TA (en) * 2012-03-08 2014-11-27 Crucell Holland Bv Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
EP4299595A3 (en) * 2014-05-02 2024-03-13 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
CN107405399B (zh) * 2015-01-02 2022-02-08 武田药品工业株式会社 针对血浆激肽释放酶和因子xii的双特异性抗体
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
MY193229A (en) * 2015-06-16 2022-09-26 Merck Patent GmbH Pd-l1 antagonist combination treatments
JP2018529719A (ja) * 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
EP3423572B1 (en) * 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
CA3007135A1 (en) * 2016-03-23 2017-09-28 Mabspace Biosciences (Suzhou) Co., Ltd Novel anti-pd-l1 antibodies
DK3484514T3 (da) * 2016-05-23 2024-01-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
EP3507367A4 (en) * 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
US20190322767A1 (en) * 2016-12-23 2019-10-24 Innate Pharma Heterodimeric antigen binding proteins

Similar Documents

Publication Publication Date Title
JP2021532085A5 (https=)
JP2021530498A5 (https=)
JP2021530989A5 (https=)
RU2019124709A (ru) КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА
ES2527961T3 (es) Anticuerpos monoclonales humanos para CD70
DE50210328D1 (de) Bispezifisches anti-cd28 antikörper-molekül
JP2020514301A5 (https=)
HRP20201517T1 (hr) Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123
HRP20210170T1 (hr) Protutijela protiv b7-h3 i konjugati protutijela s lijekom
ATE452147T1 (de) Antikörper mit korrigierten cdr
ATE187494T1 (de) Multivalente einkettige antikörper
NZ597168A (en) Dual variable domain immunoglobin and uses thereof
DE602006005526D1 (de) Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
JP2021531756A5 (https=)
RU2014100111A (ru) МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
DE602004021702D1 (de) Humanisierter antikörper gegen cd4 mit immunsuppressiven merkmalen
EA202190542A1 (ru) Сконструированные биспецифические белки
JP2019528240A5 (https=)
DK1697421T3 (da) Bispecifikke antistoffer
NZ589434A (en) Dual variable domain immunoglobulins and uses thereof
RU2013102596A (ru) МЫШИ, ЭКСПРЕССИРУЮЩИЕ ЛЕГКУЮ ЦЕПЬ С ВАРМАБЕЛЬНОЙ ОБЛАСТЬЮ α-ЧЕЛОВЕКА И КОНСТАНТНОЙ ОБЛАСТЬЮ МЫШИ
JP2021531268A5 (https=)
WO2020123662A3 (en) Fusion protein constructs for complement associated disease
ATE490983T1 (de) Humane antikörper gegen das humane glycoprotein vi und deren verwendung
IL307938B1 (en) Anti-c-met antibody drug conjugates